Forensic Analysis · General / Diversified · as of Jun 27, 2026
Cytek Biosciences, Inc. (CTKB)
A forensic read on Cytek Biosciences, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
6.2
Altman Z-score
Clean
Earnings quality
2
Forensic signals
-20.8%
ROE
$579M
Market cap
Cytek Biosciences, Inc. earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is 6.2, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-11%Return on invested capital.Return on invested capital is -11% and slipping from -1% — well below its ~9% cost of capital, so reinvested dollars may be destroying value, not building it.
12% of revStock-based comp load.Stock-based compensation ran 12% of revenue in FY2025 — about $0.19 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-33.0%
Free Cash Flow$-8.8M
Latest Revenue$201.5M
Return on Equity-19.5%
Revenue Growth YoY+0.5%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Cytek Biosciences, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about CTKB's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown